Fixed-dose combination
Betamethasone dipropionate and Calcipotriene is a fixed-dose combination of a corticosteroid and a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. MedsAcross supplies Betamethasone dipropionate and Calcipotriene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.
Source: US FDA prescribing information
Calcipotriene and Betamethasone Dipropionate Ointment combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D 3 analogue and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.
Source: US FDA prescribing information
Apply an adequate layer of Calcipotriene and Betamethasone Dipropionate Ointment to the affected area(s) once daily for up to 4 weeks. Calcipotriene and Betamethasone Dipropionate Ointment should be rubbed in gently and completely. Patients should wash their hands after applying Calcipotriene and Betamethasone Dipropionate Ointment. Therapy should be discontinued when control is achieved. Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week. Treatment of more than 30% body surface area is not recommended. Calcipotriene and Betamethasone Dipropionate Ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Hypercalcemia and hypercalciuria have been observed. If either occurs, discontinue treatment until parameters of calcium metabolism normalize. Calcipotriene and Betamethasone Dipropionate Ointment can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factors include the use of high-potency topical corticosteroid, use over a large surface area or to areas under occlusion, prolonged use, concomitant use of more than one corticosteroid-containing product, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop. Calcipotriene and Betamethasone Dipropionate Ointment may increase the risk of cataract and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist.
Source: US FDA prescribing information
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥1%) are pruritus and scaly rash.
Source: US FDA prescribing information
Store Calcipotriene and Betamethasone Dipropionate Ointment between 20°C - 25°C (68°F - 77°F), excursions permitted between 15°C - 30°C (59°F - 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Betamethasone dipropionate and Calcipotriene, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Betamethasone dipropionate and Calcipotriene 0.643 mg/50 mcg per g ointmentTopicalGeneric name | Betamethasone dipropionate and Calcipotriene | — | US FDA | Available on request |
| Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspensionTopicalGeneric name | Betamethasone dipropionate and Calcipotriene | — | US FDA | Available on request |
| Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g ointmentTopicalGeneric name | Betamethasone dipropionate and Calcipotriene | — | US FDA | Available on request |
| Betamethasone dipropionate and Calcipotriene 50 mg/50 mcg per g topical suspensionTopicalGeneric name | Betamethasone dipropionate and Calcipotriene | — | US FDA | Available on request |
| Enstilar 0.5 mg/50 mcg per g foamTopical | Betamethasone dipropionate and Calcipotriene | LEO Pharma | US FDA | Available on request |
| Taclonex 0.5 mg/50 mcg per g topical suspensionTopical | Betamethasone dipropionate and Calcipotriene | LEO Pharma | US FDA | Available on request |
| Attero 0.5 mg/0.05 mg per g topical solutionTopical | Betamethasone dipropionate and Calcipotriene | Perfero Pharma | US FDA | Available on request |
| Wynzora 64 mg/50 mcg per g creamTopical | Betamethasone dipropionate and Calcipotriene | MC2 Therapeutics | US FDA | Available on request |
4 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 9 January 2006 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 8 presentations of Betamethasone dipropionate and Calcipotriene and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Betamethasone dipropionate and Calcipotriene, including Attero, Enstilar, Taclonex, Wynzora.
Yes. The US FDA first approved Betamethasone dipropionate and Calcipotriene on 9 January 2006, according to Drugs@FDA.
No listed presentation of Betamethasone dipropionate and Calcipotriene is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.